title: Current approaches in treatment of triple-negative breast cancer.
abstract: Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest that they respond to chemotherapy better than other types of breast cancer, prognosis remains poor. This is due to: shortened disease-free interval in the adjuvant and neoadjuvant setting and a more aggressive course in the metastatic setting.
authors.affiliation: Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura 35516, Egypt.
authors.forename: Hanan Ahmed
authors.initials: HA
authors.lastname: Wahba
authors.affiliation: Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura 35516, Egypt.
authors.forename: Hend Ahmed
authors.initials: HA
authors.lastname: El-Hadaad
keywords: Breast cancer; HER2; triple-negative